Willenken partner and trial lawyer, Paul Loh is honored to be recognized among Daily Journal’s “Leading Commercial Litigators” for the second consecutive year.
In the third edition of Daily Journal‘s Leading Commercial Litigators supplement, the publication honors the best commercial and bet-the-company litigators across the country. Paul has now tried over 120 jury trials, court trials, and arbitrations during his impressive career.
The Daily Journal highlights Paul’s extensive trial expertise, including a significant win for AbbVie in a high-stakes trial against Takeda concerning the breach of a pharmaceutical supply contract.
“[T]his case is significant not only because of the complex, high financial stakes, but also because it concerned a critical, life-extending cancer drug, Lupron, which is the gold standard for the treatment of advanced prostate cancer,” Paul said about the AbbVie case.
“I am particularly proud of the fact that I led an all-diverse team comprised entirely of women and people of color to achieve this outstanding result,” Paul said about the remarkable verdict in favor of AbbVie in the amount of $506 million.
To read Daily Journal’s 2025 Leading Commercial Litigators profile on Paul, click here.